Peroxisome proliferator-activated receptor-γ and growth inhibition by its ligands in prostate cancer

Jemal, 2003, Cancer statistics, CA Cancer J Clin, 53, 5, 10.3322/canjclin.53.1.5 Mangelsdorf, 1995, The nuclear receptor superfamily: the second decade, Cell, 83, 835, 10.1016/0092-8674(95)90199-X Yu, 1995, Differential activation of peroxisome proliferator-activated receptors by eicosanoids, J Biol Chem, 270, 23975, 10.1074/jbc.270.41.23975 Qi, 2000, Peroxisome proliferator-activated receptors, coactivators, and downstream targets, Cell Biochem Biophys, 32, 187, 10.1385/CBB:32:1-3:187 Kliewer, 2001, Peroxisome proliferator-activated receptors: from genes to physiology, Recent Prog Horm Res, 56, 239, 10.1210/rp.56.1.239 Kim, 2001, Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development, Mol Genet Metab, 74, 362, 10.1006/mgme.2001.3242 Soret, 1999, Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture, J Endocrinol, 161, 517, 10.1677/joe.0.1610517 Fontaine, 2003, The orphan nuclear receptor Rev-Erbβ is a peroxisome proliferator-activated receptor (PPAR)-γ target gene and promotes PPAR-γ-induced adipocyte differentiation, J Biol Chem, 278, 37672, 10.1074/jbc.M304664200 Mueller, 1998, Terminal differentiation of human breast cancer through PPAR-γ, Mol Cell, 1, 465, 10.1016/S1097-2765(00)80047-7 Allred, 2005, Selective activation of PPARgamma in breast, colon, and lung cancer cell lines, Mol Cell Endocrinol, 235, 21, 10.1016/j.mce.2005.02.003 Nomura, 2006, Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues, J Exp Clin Cancer Res, 25, 443 Cesario, 2006, Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer, Cancer Lett, 240, 225, 10.1016/j.canlet.2005.09.010 Kristiansen, 2006, Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times, Clin Cancer Res, 12, 6444, 10.1158/1078-0432.CCR-06-0834 Soares, 2005, Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPAR gamma, Biochem Biophys Res Commun, 337, 521, 10.1016/j.bbrc.2005.09.085 Murphy, 2000, PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer, Trends Pharmacol Sci, 21, 469, 10.1016/S0165-6147(00)01559-5 Olefsky, 2000, PPAR gamma and the treatment of insulin resistance, Trends Endocrinol Metab, 11, 362, 10.1016/S1043-2760(00)00306-4 Willson, 2001, Peroxisome proliferator-activated receptor gamma and metabolic disease, Annu Rev Biochem, 70, 341, 10.1146/annurev.biochem.70.1.341 Motomura, 2004, Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells, Int J Cancer, 108, 41, 10.1002/ijc.11561 Han, 2004, Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells, Clin Cancer Res, 10, 1911, 10.1158/1078-0432.CCR-03-0985 Radhakrishnan, 2005, The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines, Cell Cycle, 4, 582, 10.4161/cc.4.4.1583 Fujii, 2004, The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest, Anticancer Res, 24, 1409 Nakanishi, 1995, Identification of the active region of the DNA synthesis inhibitory gene p21 Sdi1/CIP1/WAF1, EMBO J, 14, 555, 10.1002/j.1460-2075.1995.tb07031.x Eligini, 2002, 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade, Thromb Haemost, 7, 524, 10.1055/s-0037-1613247 Kubota, 1998, Ligand for peroxisome proliferator-activated receptor gamma has potent antitumor effects against human prostate cancer both in vitro and in vivo, Cancer Res, 58, 3344 Elstner, 1998, Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc Natl Acad Sci USA, 95, 8806, 10.1073/pnas.95.15.8806 Fulzele, 2007, 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors, Anticancer Drugs, 11, 65 Theocharis, 2004, Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators, Cancer Treat Rev, 30, 545, 10.1016/j.ctrv.2004.04.004 He, 2004, Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance, Mol Cell, 16, 425, 10.1016/j.molcel.2004.09.036 Estebanez-Perpina, 2005, The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor, J Biol Chem, 280, 8060, 10.1074/jbc.M407046200 Edwards, 2004, The role of c-Jun and c-Fos expression in androgen-independent prostate cancer, J Pathol, 204, 153, 10.1002/path.1605 Chen, 2006, c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation, Oncogene, 25, 7212, 10.1038/sj.onc.1209705 Shappell, 2001, 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells, Cancer Res, 61, 497